BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
EPS Growth %: +1,016.7%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: +1,016.7%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.47), $0.12 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $230.9 million versus the consensus estimate of $189.01 million.
BioMarin Pharma sees FY2015 revenue of $885-915 million, versus the consensus of $880.6 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
